The Skaggs School of Pharmacy & Pharmaceutical Sciences

Joseph D. Ma

Dr. Joseph Ma received his Pharmacy Doctorate from the University of California, San Francisco. He then completed a 2-year post doctoral fellowship in clinical pharmacology/drug metabolism at Bassett Healthcare, Cooperstown, NY under the mentorship of Joseph S. Bertino, Jr. PharmD, FCP and Anne N. Nafziger, MD, PhD.

Dr Ma joined the faculty in 2007 and serves as co-chair for the winter quarter Therapeutics course. He also lectures several hours in the oncology section for Therapeutics. In addition, he will also be implementing an early phase clinical trial team that will assist in the development and management of phase I clinical trials in oncology at the Moores Cancer Center.

Research Interests

His current research interests are in examining inter- and intra-individual pharmacokinetic and pharmacodynamic variability in special populations.

Selected Publications

Ma JD, Spalding JR, Lee LS, MacDougall C, Alldredge BK. Pharmacy Postdoctoral Training Programs - Are they Right for You? California Pharmacist Spring 2004: 46-49.

Ma JD, Nafziger AN, Kashuba ADM, Kim MJ, Gaedigk A, Rowland E, Kim JS, Bertino JS, Jr. Limited Sampling Strategy of S-warfarin Concentrations but not Warfarin S/R Ratios Accurately Predict S-warfarin AUC during Baseline and Inhibition in CYP2C9 Extensive Metabolizers. Journal of Clinical Pharmacology 2004; 44:570-576.

Ma JD, Nafziger AN, Bertino JS, Jr. Genetic Polymorphisms of Cytochrome P450 Enzymes and the Effect on Interindividual, Pharmacokinetic Variability in Extensive Metabolizers. Journal of Clinical Pharmacology 2004; 44:447-456.

Ma JD, Nafziger AN, Rhodes G, Liu S, Gartung AM, Bertino JS, Jr. The Effect of Oral Pleconaril on Hepatic Cytochrome P450 3A Activity in Healthy Adults Using Intravenous Midazolam as a Probe. Journal of Clinical Pharmacology 2006; 46:103-108.

Ma JD, Nafziger AN, Villano SA, Gaedigk A, Bertino JS, Jr. Maribavir Pharmacokinetics and the Effects of Multiple-Dose Maribavir on Cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-Acetyltransferase-2 (NAT-2), and Xanthine Oxidase (XO) Activities in Healthy Adults. Antimicrobial Agents and Chemotherapy 2006; 50:1130-1135.

Ma JD, Nafziger AN, Rhodes G, Liu S, Bertino JS, Jr. Duration of Pleconaril Effect on Cytochrome P450 3A Activity in Healthy Adults Using the Oral Biomarker Midazolam. Drug Metabolism and Disposition 2006; 34:783-785.

List of Publications in Pub Med